Piper Sandler analyst David Amsellem raised the firm’s price target on AbbVie (ABBV) to $289 from $284 and keeps an Overweight rating on the shares following quarterly results. The firm cites higher Skyrizi estimates in 2026-plus and higher estimates for key products in the Neuroscience segment, which it believes remains a largely under-the-radar business.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV: